Nurexone Biologic Inc

As of June 30, 2026, Nurexone Biologic Inc carries a market capitalization of 30.23M, placing it among publicly traded companies globally. Its enterprise value stands at 29.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nurexone Biologic Inc's next confirmed earnings release is scheduled for November 20, 2026.

As of June 30, 2026, Nurexone Biologic Inc has 94.46M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Nurexone Biologic Inc maintains a current ratio of 1.21, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.11, indicating elevated leverage, while an interest coverage ratio of -261.65 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Nurexone Biologic Inc posted a negative return on equity (ROE) of -450.96, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -230.17, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 17.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Nurexone Biologic Inc's stock has declined approximately 21.95% over the past 52 weeks. The 50-day moving average sits at 0.38, while the 200-day moving average is 0.37.

Over the twelve months ended June 30, 2026, Nurexone Biologic Inc generated - - in revenue and converted that into -5.52M in net income, yielding earnings per share of -0.06. EBITDA reached -5.27M, while operating income came in at -5.46M.

As of June 30, 2026, Nurexone Biologic Inc holds 880,551.80 in cash and equivalents against 45,515.60 in total debt, resulting in a net debt position of -880,551.80. Total book value stands at 1.11M, with working capital of 174,184.70 providing operational flexibility.

Nurexone Biologic Inc produced -4.07M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -49,892.10 in capital expenditures, free cash flow totaled -4.12M - equivalent to -0.05 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -15.11: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -12.78, meaning Nurexone Biologic Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Nurexone Biologic Inc's most recent stock split took place on June 22, 2022 with a 10:1 split ratio.

As of June 30, 2026, Nurexone Biologic Inc has an Altman Z-Score of -7.91, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.